Philippe Bedard
Philippe Bedard
Princess Margaret Cancer Centre
Verified email at uhn.ca
Title
Cited by
Cited by
Year
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
9942013
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium
Cancer discovery 7 (8), 818-831, 2017
4832017
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ...
New England Journal of Medicine 382 (7), 597-609, 2020
3962020
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ...
Nature 563 (7732), 579-583, 2018
3402018
The genetic basis for cancer treatment decisions
JE Dancey, PL Bedard, N Onetto, TJ Hudson
Cell 148 (3), 409-420, 2012
3392012
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
HA Azim, S Michiels, PL Bedard, SK Singhal, C Criscitiello, M Ignatiadis, ...
Clinical cancer research 18 (5), 1341-1351, 2012
3162012
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2014
3052014
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy
F Cardoso, PL Bedard, EP Winer, O Pagani, E Senkus-Konefka, ...
Journal of the National Cancer Institute 101 (17), 1174-1181, 2009
2652009
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance
C Kollmannsberger, T Tandstad, PL Bedard, G Cohn-Cedermark, ...
J Clin Oncol 33 (1), 51-7, 2015
2422015
Luminal-B breast cancer and novel therapeutic targets
B Tran, PL Bedard
Breast Cancer Research 13 (6), 1-10, 2011
2332011
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with …
PL Bedard, J Tabernero, F Janku, ZA Wainberg, L Paz-Ares, ...
Clinical Cancer Research 21 (4), 730-738, 2015
2242015
AKT inhibition in solid tumors with AKT1 mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
1992017
Cancer genomics: technology, discovery, and translation
B Tran, JE Dancey, S Kamel-Reid, JD McPherson, PL Bedard, AM Brown, ...
J Clin Oncol 30 (6), 647-660, 2012
1942012
Novel patterns of response under immunotherapy
E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, ...
Annals of Oncology 30 (3), 385-396, 2019
1792019
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, ...
Annals of Oncology 29 (9), 1895-1902, 2018
1782018
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8 (1), 1-12, 2016
1652016
Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ...
Clinical Cancer Research 24 (12), 2804-2811, 2018
1622018
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen
Annals of Oncology 26 (9), 1824-1829, 2015
1612015
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
E de Azambuja, PL Bedard, T Suter, M Piccart-Gebhart
Targeted oncology 4 (2), 77-88, 2009
1292009
Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast …
HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ...
Cancer research 76 (4 Supplement), S5-07-S5-07, 2016
1272016
The system can't perform the operation now. Try again later.
Articles 1–20